Olema Pharmaceuticals, Inc. (OLMA)
NASDAQ$4.41+0.04 (0.92%)
Market Cap
$298.62M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
41 of 924
Rank in Industry
31 of 527
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
OLMA Insider Trading Activity
OLMA Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $11,187,644 | 3 | 11 |
Sells | $65,670,092 | 24 | 89 |
Related Transactions
| Graham G. Walmsley | director | 2 | $9.46M | 3 | $26.91M | $-17.45M |
| Bain Capital Life Sciences Investors, LLC | 10 percent owner | 1 | $1.73M | 0 | $0 | $1.73M |
| Myles David C. | CH. DISCOV. & NON-CLIN DEV OFF | 0 | $0 | 2 | $234,916 | $-234,916 |
| Zojwalla Naseem | CHIEF MEDICAL OFFICER | 0 | $0 | 2 | $250,456 | $-250,456 |
| Kovacs Shane William Charles | CH. OPERATING & FINANCIAL OFF. | 0 | $0 | 2 | $316,703 | $-316,703 |
| Bohen Sean | PRESIDENT AND CEO | 0 | $0 | 2 | $986,365 | $-986,365 |
| Harmon Cyrus | director | 0 | $0 | 12 | $1.18M | $-1.18M |
| Paradigm Biocapital Advisors LP | 10 percent owner | 0 | $0 | 1 | $35.8M | $-35.8M |
About Olema Pharmaceuticals, Inc.
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema …
Insider Activity of Olema Pharmaceuticals, Inc.
Over the last 12 months, insiders at Olema Pharmaceuticals, Inc. have bought $11.19M and sold $65.67M worth of Olema Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Olema Pharmaceuticals, Inc. have bought $28.91M and sold $25.89M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Graham G. Walmsley (director) — $9.46M. Bain Capital Life Sciences Investors, LLC (10 percent owner) — $1.73M.
The last purchase of 300,000 shares for transaction amount of $1.73M was made by Bain Capital Life Sciences Investors, LLC (10 percent owner) on 2025‑01‑08.
List of Insider Buy and Sell Transactions, Olema Pharmaceuticals, Inc.
| 2025-01-08 | Bain Capital Life Sciences Investors, LLC | 10 percent owner | 300,000 0.395% | $5.76 | $1.73M | -11.30% | ||
| 2024-12-17 | Sale | Graham G. Walmsley | director | 700,761 1.3522% | $6.75 | $4.73M | -10.42% | |
| 2024-12-17 | Graham G. Walmsley | director | 700,761 1.3522% | $6.75 | $4.73M | -10.42% | ||
| 2024-12-13 | Sale | Graham G. Walmsley | director | 700,761 1.2508% | $6.75 | $4.73M | -18.52% | |
| 2024-12-13 | Graham G. Walmsley | director | 700,761 1.2508% | $6.75 | $4.73M | -18.52% | ||
| 2024-12-11 | Sale | Harmon Cyrus | director | 8,137 0.0148% | $8.68 | $70,597 | -34.36% | |
| 2024-12-11 | Sale | Myles David C. | CH. DISCOV. & NON-CLIN DEV OFF | 13,614 0.0247% | $8.68 | $118,116 | -34.36% | |
| 2024-12-11 | Sale | Kovacs Shane William Charles | CH. OPERATING & FINANCIAL OFF. | 18,356 0.0333% | $8.68 | $159,259 | -34.36% | |
| 2024-12-11 | Sale | Bohen Sean | PRESIDENT AND CEO | 57,174 0.1037% | $8.68 | $496,052 | -34.36% | |
| 2024-12-11 | Sale | Zojwalla Naseem | CHIEF MEDICAL OFFICER | 14,522 0.0264% | $8.68 | $125,994 | -34.36% | |
| 2024-12-10 | Sale | Harmon Cyrus | director | 8,256 0.0145% | $9.37 | $77,359 | -42.48% | |
| 2024-12-10 | Sale | Myles David C. | CH. DISCOV. & NON-CLIN DEV OFF | 12,452 0.0218% | $9.38 | $116,800 | -42.48% | |
| 2024-12-10 | Sale | Kovacs Shane William Charles | CH. OPERATING & FINANCIAL OFF. | 16,803 0.0294% | $9.37 | $157,444 | -42.48% | |
| 2024-12-10 | Sale | Bohen Sean | PRESIDENT AND CEO | 52,328 0.0917% | $9.37 | $490,313 | -42.48% | |
| 2024-12-10 | Sale | Zojwalla Naseem | CHIEF MEDICAL OFFICER | 13,283 0.0233% | $9.37 | $124,462 | -42.48% | |
| 2024-08-01 | Sale | Paradigm Biocapital Advisors LP | 10 percent owner | 2.4M 3.888% | $14.91 | $35.8M | -38.52% | |
| 2024-07-30 | Sale | Harmon Cyrus | director | 934 0.0017% | $15.55 | $14,524 | -34.72% | |
| 2024-07-29 | Sale | Harmon Cyrus | director | 4,066 0.0075% | $15.58 | $63,348 | -32.55% | |
| 2024-07-11 | Sale | Harmon Cyrus | director | 5,000 0.0099% | $12.26 | $61,300 | -9.00% | |
| 2024-06-28 | Sale | Harmon Cyrus | director | 20,000 0.0348% | $10.77 | $215,400 | +4.81% |
Total: 90
*Gray background shows transactions not older than one year
Insider Historical Profitability
5.02%
| Bain Capital Life Sciences Investors, LLC | 10 percent owner | 7800000 11.4147% | $34.09M | 1 | 0 | |
| Graham G. Walmsley | director | 1408875 2.0618% | $6.16M | 5 | 3 | <0.0001% |
| Paradigm Biocapital Advisors LP | 10 percent owner | 783118 1.146% | $3.42M | 1 | 1 | +0.94% |
| Kovacs Shane William Charles | CH. OPERATING & FINANCIAL OFF. | 543549 0.7954% | $2.38M | 2 | 4 | +243.62% |
| BVF PARTNERS L P/IL | 4688954 6.8619% | $20.49M | 3 | 0 | <0.0001% |
*Gray background shows insiders who have made transactions during last year
Historical Insider Profitability vs. Competitors
$99,438,720 | 81 | 6.74% | $289.16M | |
$5,911,307 | 70 | -1.38% | $320.89M | |
$41,446,394 | 27 | 12.91% | $341.56M | |
$56,550,550 | 22 | 50.17% | $293.04M | |
$14,865,077 | 18 | -28.56% | $353.14M |
OLMA Institutional Investors: Active Positions
| Increased Positions | 92 | +73.02% | 21M | +35.51% |
| Decreased Positions | 49 | -38.89% | 7M | -11.92% |
| New Positions | 38 | New | 13M | New |
| Sold Out Positions | 10 | Sold Out | 1M | Sold Out |
| Total Postitions | 169 | +34.13% | 73M | +23.59% |
OLMA Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Bain Capital Life Sciences Investors, Llc | $32,645.00 | 10.99% | 7.47M | +7M | New | 2024-12-31 |
| Paradigm Biocapital Advisors Lp | $31,923.00 | 10.74% | 7.3M | +2M | +32.73% | 2024-12-31 |
| Bvf Inc/Il | $24,978.00 | 8.41% | 5.72M | -3M | -37.44% | 2024-12-31 |
| Blackrock, Inc. | $16,562.00 | 5.57% | 3.79M | -57,639 | -1.5% | 2024-12-31 |
| Point72 Asset Management, L.P. | $16,042.00 | 5.4% | 3.67M | -16,548 | -0.45% | 2024-12-31 |
| Deep Track Capital, Lp | $15,045.00 | 5.06% | 3.44M | -557,167 | -13.93% | 2024-12-31 |
| Logos Global Management Lp | $14,023.00 | 4.72% | 3.21M | 0 | 0% | 2024-12-31 |
| Mpm Bioimpact Llc | $12,728.00 | 4.28% | 2.91M | +231,954 | +8.65% | 2024-12-31 |
| Vanguard Group Inc | $11,733.00 | 3.95% | 2.69M | +152,117 | +6.01% | 2024-12-31 |
| Lightspeed Management Company, L.L.C. | $8,438.00 | 2.84% | 1.93M | +2M | New | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Analyst Recommendations
Analyst Price Targets
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.